Table 1.
Anti-allergy premedication groups and Cmab combination chemotherapy regimens.
| Group | Combination | Chemotherapy | H1AT (mg) | DEX (mg) | H2AT (mg) | 3-day APR |
|---|---|---|---|---|---|---|
| A | Cmab | RT + Cmab Cmab alone | 5 | 6.6 | – | – |
| Bc | Cmab + PTX (+CBDCAa) | PTX + Cmab CBDCA + PTX + Cmab | 5 | 6.6 | 20 | – |
| C | Cmab + CBDCAb + 5FU | CBDCA + 5FU + Cmab | 5 | 9.9 | – | – |
| D | Cmab + CDDP (+5FU or DOC) | DOC + CDDP + Cmab CDDP + 5FU + Cmab | 5 | 13.2 a | – | ○ |
a
Three days of oral aprepitant: 125 mg on day 1, 80 mg on days 2–3
b
Calculated using target AUC = 2
c
Only Group B was administrated Cmab from 60 to 90 min after premedication because of the administration of other chemotherapy (paclitaxel for 60 min with or without CBDCA for 30 min)
5FU, 5-fluorouracil; APR, aprepitant; CBDCA, carboplatin; CDDP, cisplatin; Cmab, cetuximab; DOC, docetaxel; H1AT, antihistamine H1-receptor antagonist (d-chlorpheniramine); H2AT, antihistamine H2-receptor antagonist (famotidine); PTX, paclitaxel; RT, radiotherapy.